Stay updated with breaking news from Annual Bleeding Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CSL's HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON, Oct. 26, 2023 /CNW/ -- Global biotechnology leader CSL today announced...
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual...
Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX ...
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the